Third Arc Bio vs Biconomy
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors. Platform spans oncology and autoimmune.
About
Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.
Web3 authentication and account abstraction infrastructure enabling gasless transactions and simplified dApp onboarding; ERC-4337 implementation allows dApps to sponsor gas fees on behalf of users and accept ERC-20 token gas payment for mainstream-accessible wallet experiences.
About
Biconomy is a Web3 infrastructure platform focused on making decentralized applications usable by mainstream audiences who are not familiar with cryptocurrency gas mechanics. Its core product implements account abstraction via ERC-4337, allowing dApp developers to sponsor gas fees on behalf of users, accept gas payment in ERC-20 tokens instead of native currency, and batch multiple on-chain transactions into a single user action. These capabilities transform the user experience from one requiring native token balances and technical awareness into something closer to a conventional web application workflow.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.